keyword
MENU ▼
Read by QxMD icon Read
search

DMARDs

keyword
https://www.readbyqxmd.com/read/28329487/apremilast-for-the-treatment-of-psoriatic-arthritis
#1
Brent C Martin, Logan W Thomas, Francis J Dann
Psoriatic arthritis (PsA) is a chronic inflammatoryarthropathy that affects joints and entheses andis associated with psoriasis (PsO). There are fiveclinical patterns of PsA: symmetrical polyarthritis,distal interphalangeal arthropathy, asymmetricaloligoarthritis, arthritis mutilans, and spondylitis, withor without sacroiliitis. Concerning PsA, the goals oftherapy are to control inflammation, prevent articulardamage, and reduce discomfort in the affected joints.Although there are many therapeutic options forthe treatment of PsAs, physicians most often beginwith nonsteroidal anti-inflammatory drugs (NSAIDs)for mild disease...
February 15, 2017: Dermatology Online Journal
https://www.readbyqxmd.com/read/28324149/-outpatient-care-and-disease-burden-of-rheumatoid-arthritis-results-of-a%C3%A2-linkage-of-claims-data-and-a%C3%A2-survey-of-insured-persons
#2
K Albrecht, A Luque Ramos, J Callhoff, F Hoffmann, K Minden, A Zink
BACKGROUND: Healthcare of patients with rheumatoid arthritis (RA) in Germany has mainly been evaluated in the past in RA cohorts from specialized arthritis centers. This study investigated rheumatological care on a population basis, using claims data from a nationwide statutory health insurance fund (BARMER GEK) in combination with patient-reported outcomes from a questionnaire survey of insured persons with RA. METHODS: Data from insurants aged 18-79 years with M05 (seropositive RA) or M06 (other RA, ICD-10) diagnoses were analyzed concerning diagnostics, medication and prescribing physician...
March 21, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28321492/anti-toxoplasma-antibodies-in-egyptian-rheumatoid-arthritis-patients
#3
Abeer A El-Henawy, Eman Abdel Razek Hafez, Nairmen Nabih, Naglaa M Shalaby, Mervat Mashaly
OBJECTIVE: To assess seroprevalence of anti-Toxoplasma gondii antibodies; both IgG and IgM in Egyptian rheumatoid arthritis (RA) patients versus a non-RA group and to compare anti-Toxoplasma antibodies seroprevalence among RA patients receiving traditional treatment and RA patients treated with biologic drug. METHODS: 60 RA patients and 60 healthy controls were enrolled in the study. Patients were categorized into two groups: one group included 30 patients receiving disease modifying anti-rheumatic drugs (DMARDs), while the other group included 30 patients receiving biologic agent, infliximab, a TNF-α antagonist...
March 20, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28320050/the-practice-pattern-of-hepatitis-b-testing-in-rheumatoid-arthritis-patients-a-cross-national-comparison-between-us-and-taiwan
#4
Tzu-Chieh Lin, Nikroo Hashemi, Seoyoung C Kim, Yea-Huei Kao Yang, Kazuki Yoshida, Sara Tedeschi, Rishi Desai, Daniel H Solomon
OBJECTIVE: The Hepatitis B Virus (HBV) testing rates and patterns in rheumatoid arthritis (RA) patients starting disease modifying anti-rheumatic drugs (DMARDs) have not been well studied. We describe and compare the practice patterns of HBV testing among RA patients in U.S. and Taiwan. METHODS: We conducted a retrospective cohort study including RA patients starting first DMARD in U.S. or Taiwan. The first date patients newly received any DMARD was defined as the index date, and the 1-year period before the index date was the baseline period...
March 20, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28301793/advances-in-rheumatoid-arthritis
#5
Graeme Jones, Peter Nash, Stephen Hall
There are now eight approved biological disease-modifying antirheumatic drugs (bDMARDs), two biosimilars and one targeted synthetic DMARD in Australia with a number of new products and biosimilars in the pipeline. bDMARDs have excellent efficacy, especially when combined with traditional DMARDs, and a well characterised but manageable safety profile. These expanded therapeutic options have revolutionised patient care and made remission (including drug free remission) a realistic goal. Evidence of a "window of opportunity" that changes the long term phenotype of the disease has been well established, so therapy should be commenced as early as possible in the disease process and a shared care model between general practitioner and rheumatologist provides the best outcomes...
March 20, 2017: Medical Journal of Australia
https://www.readbyqxmd.com/read/28299917/the-impact-on-disability-of-initial-treatment-with-methotrexate-in-patients-with-rheumatoid-arthritis-results-from-the-mari-study
#6
M Manara, L Arcarese, G Bianchi, V Corbelli, O Epis, R Laurenti, A Migliore, M Muratore, A Roncaglione, M Rossini, M Savo, L Sinigaglia
The study aimed to assess in a population of subjects with rheumatoid arthritis (RA) treated with methotrexate (MTX) how the initial approach to the treatment influenced subsequent disability. We performed a cross-sectional analysis of data collected during the baseline visit of the MARI study, a multicenter observational study on patients with RA on treatment with MTX for at least 12 months. Subjects who fulfilled the Health Assessment Questionnaire (HAQ) were included in the evaluation. For every patient we retrospectively evaluated the disease duration, the duration of symptoms before the diagnosis, the time elapsed before first MTX treatment, the initial MTX dose, and the concomitant medications in the first six months of therapy...
December 31, 2016: Reumatismo
https://www.readbyqxmd.com/read/28298374/safety-of-synthetic-and-biological-dmards-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-management-of-rheumatoid-arthritis
#7
Sofia Ramiro, Alexandre Sepriano, Katerina Chatzidionysiou, Jackie L Nam, Josef S Smolen, Désirée van der Heijde, Maxime Dougados, Ronald van Vollenhoven, Johannes W Bijlsma, Gerd R Burmester, Marieke Scholte-Voshaar, Louise Falzon, Robert B M Landewé
OBJECTIVES: To assess the safety of synthetic (s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA) to inform the European League Against Rheumatism recommendations for the management of RA. METHODS: Systematic literature review (SLR) of observational studies comparing any DMARD with another intervention for the management of patients with RA. All safety outcomes were included. A comparator group was required for the study to be included...
March 15, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28297165/dmards-in-psoriasis-a-critical-appraisal
#8
K Eyerich
No abstract text is available yet for this article.
March 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28296761/polymorphisms-and-pharmacogenomics-for-the-toxicity-of-methotrexate-monotherapy-in-patients-with-rheumatoid-arthritis-a-systematic-review-and-meta-analysis
#9
Qi Qiu, Jing Huang, Yang Lin, Xiaoming Shu, Huizheng Fan, Zhihua Tu, Youwen Zhou, Cheng Xiao
BACKGROUND: Methotrexate (MTX) is widely used and considered a first-line disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). However, 10% to 30% of patients discontinue therapy within a year of starting the treatment, usually because of undesirable side effects. Many of the relevant genes have been investigated to estimate the association between gene polymorphisms and MTX toxicity in RA patients, although inconsistent results have been reported...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28294642/cost-effectiveness-of-sequenced-treatment-of-rheumatoid-arthritis-with-targeted-immune-modulators
#10
Jeroen P Jansen, Devin Incerti, Alex Mutebi, Desi Peneva, Joanna MacEwan, Bradley Stolshek, Primal Kaur, Mahdi Gharaibeh, Vibeke Strand
AIMS: To determine the cost-effectiveness of treatment sequences of biologic disease-modifying antirheumatic drugs or Janus kinase/STAT pathway inhibitors (collectively referred to as bDMARDs) versus conventional DMARDs (cDMARDs) from the US societal perspective for treatment of patients with moderately to severely active rheumatoid arthritis (RA) with inadequate responses to cDMARDs. MATERIALS AND METHODS: We developed an individual patient simulation model that assesses the impact of treatments on disease based on clinical trial data and real-world evidence...
March 15, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28293446/real-life-experience-of-using-conventional-disease-modifying-anti-rheumatic-drugs-dmards-in-psoriatic-arthritis-psa-retrospective-analysis-of-the-efficacy-of-methotrexate-sulfasalazine-and-leflunomide-in-psa-in-comparison-to-spondyloarthritides-other-than-psa
#11
Euthalia Roussou, Aicha Bouraoui
OBJECTIVE: With the aim of assessing the response to treatment with conventional disease-modifying anti-rheumatic drugs (DMARDs) used in patients with psoriatic arthritis (PsA), data on methotrexate, sulfasalazine (SSZ), and leflunomide were analyzed from baseline and subsequent follow-up (FU) questionnaires completed by patients with either PsA or other spondyloarthritides (SpAs). MATERIAL AND METHODS: A single-center real-life retrospective analysis was performed by obtaining clinical data via questionnaires administered before and after treatment...
March 2017: European Journal of Rheumatology
https://www.readbyqxmd.com/read/28293115/topical-medication-utilization-and-health-resources-consumption-in-adult-patients-affected-by-psoriasis-findings-from-the-analysis-of-administrative-databases-of-local-health-units
#12
Valentina Perrone, Diego Sangiorgi, Stefano Buda, Luca Degli Esposti
AIM: The objectives of this study were to: 1) analyze the drug utilization pattern among adult psoriasis patients who were newly prescribed with topical medication; and 2) assess their adherence to topical therapy and the possibility of switching to other strategies in the treatment process. METHODS: An observational retrospective analysis was conducted based on administrative databases of two Italian local health units. All adult subjects who were diagnosed with psoriasis or who were newly prescribed for topical medication with at least one prescription between January 1, 2010, and December 31, 2014, were screened...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28290136/baricitinib-first-global-approval
#13
Anthony Markham
Baricitinib (Olumiant™) is an orally-administered, small-molecule, janus-associated kinase (JAK) inhibitor developed by Eli Lilly and Incyte Corporation for the treatment of rheumatoid arthritis (RA), atopic dermatitis and systemic lupus erythematosus. JAKs transduce intracellular signals from cell surface receptors for various cytokines and growth factors involved in inflammation and immune function, suggesting JAK inhibitors may be of therapeutic benefit in inflammatory conditions. In February 2017, baricitinib was approved in the EU, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)...
March 13, 2017: Drugs
https://www.readbyqxmd.com/read/28284845/risks-of-malignancies-related-to-tofacitinib-and-biological-drugs-in-rheumatoid-arthritis-systematic-review-meta-analysis-and-network-meta-analysis
#14
José Ramón Maneiro, Alejandro Souto, Juan J Gomez-Reino
OBJECTIVE: To summarize and compare the risks of malignancies accompanying biologic DMARDs (b-DMARDs) and tofacitinib in rheumatoid arthritis (RA) in randomized clinical trials (RCTs) and long-term extension studies (LTEs). METHODS: Articles in Medline, Embase, Cochrane Library, and the Web of Science dated from 2000 to February 2015. Selection criteria were as follows: (1) focus on RCTs or LTEs in RA; (2) treatment with b-DMARDs or tofacitinib; (3) data on malignancies; and (4) a minimum follow-up of 12 weeks...
February 16, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28283512/efficacy-of-biological-disease-modifying-antirheumatic-drugs-a-systematic-literature-review-informing-the-2016-update-of-the-eular-recommendations-for-the-management-of-rheumatoid-arthritis
#15
Jackie L Nam, Kaoru Takase-Minegishi, Sofia Ramiro, Katerina Chatzidionysiou, Josef S Smolen, Désirée van der Heijde, Johannes W Bijlsma, Gerd R Burmester, Maxime Dougados, Marieke Scholte-Voshaar, Ronald van Vollenhoven, Robert Landewé
OBJECTIVES: To update the evidence for the efficacy of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) to inform European League Against Rheumatism (EULAR) Task Force treatment recommendations. METHODS: MEDLINE, EMBASE and Cochrane databases were searched for phase III or IV (or phase II, if these studies were lacking) randomised controlled trials (RCTs) published between January 2013 and February 2016. Abstracts from the American College of Rheumatology and EULAR conferences were obtained...
March 10, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28282491/biologics-or-tofacitinib-for-people-with-rheumatoid-arthritis-unsuccessfully-treated-with-biologics-a-systematic-review-and-network-meta-analysis
#16
REVIEW
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Lara J Maxwell, Rachelle Buchbinder, Maria Angeles Lopez-Olivo, Maria E Suarez-Almazor, Peter Tugwell, George A Wells
BACKGROUND: Biologic disease-modifying anti-rheumatic drugs (DMARDs: referred to as biologics) are effective in treating rheumatoid arthritis (RA), however there are few head-to-head comparison studies. Our systematic review, standard meta-analysis and network meta-analysis (NMA) updates the 2009 Cochrane overview, 'Biologics for rheumatoid arthritis (RA)' and adds new data. This review is focused on biologic or tofacitinib therapy in people with RA who had previously been treated unsuccessfully with biologics...
March 10, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28281458/biologic-treatment-for-rheumatic-disease-real-world-big-data-analysis-from-the-greek-country-wide-prescription-database
#17
Petros P Sfikakis, Vasiliki-Kalliopi Bournia, Prodromos Sidiropoulos, Dimitrios T Boumpas, Alexandros A Drosos, George D Kitas, George Konstantonis, Stamatis N Liossis, Menelaos N Manoussakis, Lazaros Sakkas, Maria Tektonidou, Athanasios G Tzioufas, Panayiotis G Vlachoyiannopoulos, Chara Kani, Panayiotis Paterakis, Panayiota Litsa, Dimitrios Vassilopoulos
OBJECTIVES: To directly assess the prevalence of inflammatory rheumatic disease under treatment with biologic disease modifying anti-rheumatic drugs (b-DMARDs) and compare treatment patterns between rheumatoid arthritis (RA) and spondyloarthropathy (SpA), including psoriatic arthritis. METHODS: The obligatory country-wide prescription electronic database covering 10.223.000 Greek citizens (95.1% of the population, 99.5% Caucasian), all of whom with fully reinbursed access to b-DMARDs, was used to retrospectively capture all patients under b-DMARDs for RA/SpA between June 2014-May 2015...
March 3, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28279189/therapeutic-strategies-of-drug-repositioning-targeting-autophagy-to-induce-cancer-cell-death-from-pathophysiology-to-treatment
#18
REVIEW
Go J Yoshida
The 2016 Nobel Prize in Physiology or Medicine was awarded to the researcher that discovered autophagy, which is an evolutionally conserved catabolic process which degrades cytoplasmic constituents and organelles in the lysosome. Autophagy plays a crucial role in both normal tissue homeostasis and tumor development and is necessary for cancer cells to adapt efficiently to an unfavorable tumor microenvironment characterized by hypo-nutrient conditions. This protein degradation process leads to amino acid recycling, which provides sufficient amino acid substrates for cellular survival and proliferation...
March 9, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28277345/a-treat-to-target-strategy-preserves-work-capacity-in-a-rheumatoid-arthritis-inception-cohort-treated-with-combination-conventional-dmard-therapy
#19
Mihir D Wechalekar, Stephen Quinn, Susan Lester, Robert G Metcalf, Ella Shanahan, Jennifer G Walker, Malcolm D Smith, Catherine L Hill, E Michael Shanahan, Susanna M Proudman
OBJECTIVES: Quantification of work disability in patients with early rheumatoid arthritis receiving conventional DMARDs according to a treat-to-target strategy. METHODS: Patients received combination conventional DMARDs, escalated to achieve DAS28(ESR) remission and completed an annual work and arthritis questionnaire. Random effect mixed modeling was used to assess associations between average hours worked per week (HWPW), and baseline prognostic factors. HWPW were compared with matched population averages...
March 9, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28274164/impact-of-immunogenicity-on-response-to-anti-tnf-therapy-in-moderate-to-severe-plaque-psoriasis-results-of-the-predir-study
#20
Mariano Ara-Martín, Pedro Herranz Pinto, Dora Pascual-Salcedo
PURPOSE: This study was conducted to examine the relationship between loss of clinical response to anti-tumor necrosis factor (TNF) therapy and the production of anti-drug antibodies (ADAs) and the potential effects of biologic immunogenicity. MATERIALS AND METHODS: This observational, non-interventional, cross-sectional study included patients with moderate-to-severe plaque psoriasis and secondary failure of adalimumab, etanercept and infliximab who were seen in the clinical practice setting...
March 8, 2017: Journal of Dermatological Treatment
keyword
keyword
86203
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"